Skip to main content

Table 2 Summary of therapeutic benefits of MSC-CM in preclinical animal models

From: Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease

CM Source Route Injury Model Outcomes Key Factor Ref.
Mouse BM-MSC IT Mouse-ALI/LPS ↓ Neutrophils in BALF
↑ M2 in BALF
IGF-1 [74]
Human BM-MSC IV Rat-Pneumonia/E. coli ↑ Survival LL-37 [81]
Rat BM-MSC IT Rat-Lung Injury/I/R ↓ Pro-inflammatory cytokines
↓ Neutrophils in BALF
↑ M2 & Treg in BALF
  [82]
Mouse BMC IN Mouse-Asthma/OVA ↓ Airway inflammation
↓ Airway hyper-responsiveness
↓ Airway smooth muscle thickness
↑ IL-10 producing Treg & macrophages
APN [83]
Mouse BM-MSC IV Neonatal Mouse-BPD/Hyperoxia ↓ Right ventricular hypertrophy
↓ Intrapulmonary arterioles muscularization
↓ Inflammatory cells & cytokines in BALF
Preserve alveoli morphology
↑ Number of BASCs
Opn
Csf1
[71, 84, 85]
Hyperoxia Preconditioned Rat BM-MSC IP Neonatal Rat- BPD/Hyperoxia ↓ PAH
↓ Right ventricular hypertrophy
↓ Pulmonary artery medial wall thickness
Improved lung structure
STC-1 [87]
Rat BM-MSC IT Rat-Lung Fibrosis/
Bleomycin
↓ Lung fibrosis
↓ AEC apoptosis
  [76]
Rat BM-MSC IV Rat-COPD/ cigarette smoke ↓ Lung emphysema
↓ Pulmonary artery medial wall thickness
↑ Number of small pulmonary vessels
Protect lung fibroblasts
  [91, 92]
  1. AEC – alveolar epithelial cell, ALI – acute lung injury, APN – adiponectin, BALF – bronchoalveolar lavage fluid, BASCs – bronchoalveolar stem cells, BM-MSC – bone marrow-derived mesenchymal stem cells, BPD – bronchopulmonary dysplasia, COPD – chronic obstructive pulmonary disease, Csf1 – macrophage colony stimulating factor 1 (M-CSF), E. coli – Escherichia coli, IN – intranasal, IP – intraperitoneally, I/R – ischemia reperfusion, IT – intratracheal, IV – intravenous, LPS – lipopolysaccharide, M2 – macrophage type 2, Opn – osteopontin, OVA – ovalbumin, PAH – pulmonary artery hypertension, STC-1 – stanniocalcin 1, Treg – regulatory T lymphocyte